Full-length TDP-43 forms toxic amyloid oligomers that are present in frontotemporal lobar dementia-TDP patients

Nature Communications

Volumn 5, Issue , 2014, Pages

  Fang, Yu Sheng ^a,b   Tsai, Kuen Jer ^c   Chang, Yu Jen ^a   Kao, Patricia ^d   Woods, Rima ^d   Kuo, Pan Hsien ^e   Wu, Cheng Chun ^c   Liao, Jhih Ying ^f   Chou, Shih Chieh ^a,f   Lin, Vinson ^g   Jin, Lee Way ^d   Yuan, Hanna S ^e   Cheng, Irene H ^f   Tu, Pang Hsien ^h   Chen, Yun Ru ^a,b  

^a GENOMICS RESEARCH CENTER   (Taiwan)

^b NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

^f NATIONAL YANG MING UNIVERSITY   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^h INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; OLIGOMER; DNA BINDING PROTEIN; EPITOPE; HYBRID PROTEIN; MONOCLONAL ANTIBODY; PROTEIN AGGREGATE; TDP-43 PROTEIN, HUMAN;

MEDICAL GEOGRAPHY; NERVOUS SYSTEM DISORDER; NEUROLOGY; PATHOGENICITY; PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DNA BINDING; FOREBRAIN; FRONTOTEMPORAL DEMENTIA; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR WEIGHT; MOUSE; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; SURFACE PROPERTY; TDP 43 PROTEINOPATHY; AMINO ACID SEQUENCE; ANIMAL; BIOSYNTHESIS; BRAIN CORTEX; CHEMISTRY; ESCHERICHIA COLI; GENE EXPRESSION; GENETICS; HEK293 CELL LINE; IMMUNOLOGY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MAMMALIAN EMBRYO; METABOLISM; MOLECULAR GENETICS; NERVE CELL; PATHOLOGY; PRIMARY CELL CULTURE; PROTEINOSIS; TUMOR CELL LINE;

MUS;

AMINO ACID SEQUENCE; AMYLOID; ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CEREBRAL CORTEX; DNA-BINDING PROTEINS; EMBRYO, MAMMALIAN; EPITOPES; ESCHERICHIA COLI; FRONTOTEMPORAL DEMENTIA; GENE EXPRESSION; HEK293 CELLS; HUMANS; INJECTIONS, INTRAVENTRICULAR; MALE; MICE; MOLECULAR SEQUENCE DATA; NEURONS; PRIMARY CELL CULTURE; PROTEIN AGGREGATES; PROTEIN AGGREGATION, PATHOLOGICAL; RECOMBINANT FUSION PROTEINS; TDP-43 PROTEINOPATHIES;

EID: 84923238777     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms5824     Document Type: Article

References (56)

1. Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130-133 (2006).
2. Arai, T. et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 351, 602-611 (2006).
3. Chen-Plotkin, A. S., Lee, V. M. & Trojanowski, J. Q. TAR DNA-binding protein 43 in neurodegenerative disease. Nat. Rev. Neurol. 6, 211-220 (2010).
4. Forman, M. S. et al. Frontotemporal dementia: clinicopathological correlations. Ann. Neurol. 59, 952-962 (2006).
5. Snowden, J. S., Neary, D. & Mann, D. M. Frontotemporal dementia. Br. J. Psychiatry 180, 140-143 (2002).
6. Kwong, L. K., Uryu, K., Trojanowski, J. Q. & Lee, V. M. TDP-43 proteinopathies: neurodegenerative protein misfolding diseases without amyloidosis. Neurosignals 16, 41-51 (2008).
7. Bosque, P. J., Boyer, P. J. & Mishra, P. A 43-kDa TDP-43 species is present in aggregates associated with frontotemporal lobar degeneration. PLoS ONE 8, e62301 (2013).
8. Strong, M. J. et al. TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein. Mol. Cell Neurosci. 35, 320-327 (2007).
9. Bigio, E. H. et al. Inclusions in frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have properties of amyloid. Acta Neuropathol. 125, 463-465 (2013).
10. Rambaran, R. N. & Serpell, L. C. Amyloid fibrils: abnormal protein assembly. Prion 2, 112-117 (2008).
11. Haass, C. & Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell. Biol. 8, 101-112 (2007).
12. Jin, M. et al. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc. Natl Acad. Sci. USA 108, 5819-5824 (2011).
13. Kayed, R. et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489 (2003).
14. Glabe, C. G. Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol. Aging 27, 570-575 (2006).
15. Glabe, C. G. & Kayed, R. Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology 66, S74-S78 (2006).
16. Wang, I. F., Wu, L. S. & Shen, C. K. TDP-43: an emerging new player in neurodegenerative diseases. Trends Mol. Med. 14, 479-485 (2008).
17. Kuo, P. H., Doudeva, L. G., Wang, Y. T., Shen, C. K. & Yuan, H. S. Structural insights into TDP-43 in nucleic-acid binding and domain interactions. Nucleic Acids Res. 37, 1799-1808 (2009).
18. Ou, S. H., Wu, F., Harrich, D., Garcia-Martinez, L. F. & Gaynor, R. B. Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J. Virol. 69, 3584-3596 (1995).
19. Chen, A. K. et al. Induction of amyloid fibrils by the C-terminal fragments of TDP-43 in amyotrophic lateral sclerosis. J. Am. Chem. Soc. 132, 1186-1187 (2010).
20. Wu, L. S., Cheng, W. C. & Shen, C. K. J. Targeted depletion of TDP-43 expression in the spinal cord motor neurons leads to the development of amyotrophic lateral sclerosis-like phenotypes in mice. J. Biol. Chem. 287, 27335-27344 (2012).
21. Wegorzewska, I., Bell, S., Cairns, N. J., Miller, T. M. & Baloh, R. H. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc. Natl Acad. Sci. USA 106, 18809-18814 (2009).
22. Johnson, B. S., McCaffery, J. M., Lindquist, S. & Gitler, A. D. A yeast TDP-43 proteinopathy model: exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc. Natl Acad. Sci. USA 105, 6439-6444 (2008).
23. Tatom, J. B. et al. Mimicking aspects of frontotemporal lobar degeneration and Lou Gehrig's disease in rats via TDP-43 overexpression. Mol. Ther. 17, 607-613 (2009).
24. Wils, H. et al. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc. Natl Acad. Sci. USA 107, 3858-3863 (2010).
25. Tsai, K. J. et al. Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLDU. J. Exp. Med. 207, 1661-1673 (2010).
26. Shodai, A. et al. Aberrant assembly of RNA recognition motif 1 links to pathogenic conversion of TAR DNA-binding protein of 43 kDa (TDP-43). J. Biol. Chem. 288, 14886-14905 (2013).
27. Chang, C. K., Chiang, M. H., Toh, E. K., Chang, C. F. & Huang, T. H. Molecular mechanism of oxidation-induced TDP-43 RRM1 aggregation and loss of function. FEBS Lett. 587, 575-582 (2013).
28. Wang, Y. T. et al. The truncated C-terminal RNA recognition motif of TDP-43 protein plays a key role in forming proteinaceous aggregates. J. Biol. Chem. 288, 9049-9057 (2013).
29. Jiang, L. L. et al. Structural transformation of the amyloidogenic core region of TAR DNA binding protein of 43 kDa (TDP-43) initiates its aggregation and cytoplasmic inclusion. J. Biol. Chem. 288, 19614-19624 (2013).
30. Saini, A. & Chauhan, V. S. Delineation of the core aggregation sequences of TDP-43 C-terminal fragment. Chembiochem 12, 2495-2501 (2011).
31. Lashuel, H. A. & Lansbury, Jr P. T. Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Q. Rev. Biophys. 39, 167-201 (2006).
32. Johnson, B. S. et al. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J. Biol. Chem. 284, 20329-20339 (2009).
33. Engelhard, M. & Evans, P. A. Kinetics of interaction of partially folded proteins with a hydrophobic dye: evidence that molten globule character is maximal in early folding intermediates. Protein Sci. 4, 1553-1562 (1995).
34. Colby, D. W. & Prusiner, S. B. Prions. Cold Spring Harb. Perspect. Biol. 3, a006833 (2011).
35. Petkova, A. T. et al. Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science 307, 262-265 (2005).
36. Roychaudhuri, R., Yang, M., Hoshi, M. M. & Teplow, D. B. Amyloid beta-protein assembly and Alzheimer disease. J. Biol. Chem. 284, 4749-4753 (2009).
37. Shu, Q. et al. The E. coli CsgB nucleator of curli assembles to beta-sheet oligomers that alter the CsgA fibrillization mechanism. Proc. Natl Acad. Sci. USA 109, 6502-6507 (2012).
38. Lasagna-Reeves, C. A., Castillo-Carranza, D. L., Guerrero-Muoz, M. J., Jackson, G. R. & Kayed, R. Preparation and characterization of neurotoxic tau oligomers. Biochemistry 49, 10039-10041 (2010).
39. Forman, M. S., Trojanowski, J. Q. & Lee, V. M. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat. Med. 10, 1055-1063 (2004).
40. Benilova, I., Karran, E. & De Strooper, B. The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat. Neurosci. 15, 349-357 (2012).
41. Lal, R., Lin, H. & Quist, A. P. Amyloid beta ion channel: 3D structure and relevance to amyloid channel paradigm. Biochim. Biophys. Acta 1768, 1966-1975 (2007).
42. Lashuel, H. A. & Lansbury, P. T. Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Q. Rev. Biophys. 39, 167-201 (2006).
43. Lin, W. L. & Dickson, D. W. Ultrastructural localization of TDP-43 in filamentous neuronal inclusions in various neurodegenerative diseases. Acta Neuropathol. 116, 205-213 (2008).
44. Hasegawa, M. et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann. Neurol. 64, 60-70 (2008).
45. Cohen, T. J., Hwang, A. W., Unger, T., Trojanowski, J. Q. & Lee, V. M. Redox signalling directly regulates TDP-43 via cysteine oxidation and disulphide cross-linking. EMBO J. 31, 1241-1252 (2012).
46. Higashi, S. et al. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. Brain Res. 1184, 284-294 (2007).
47. Davidson, Y. S. et al. TDP-43 pathological changes in early onset familial and sporadic Alzheimer's disease, late onset Alzheimer's disease and Down's syndrome: association with age, hippocampal sclerosis and clinical phenotype. Acta Neuropathol. 122, 703-713 (2011).
48. Amador-Ortiz, C. et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann. Neurol. 61, 435-445 (2007).
49. Nonaka, T. et al. Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep. 4, 124-134 (2013).
50. Liachko, N. F., Guthrie, C. R. & Kraemer, B. C. Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy. J. Neurosci. 30, 16208-16219 (2010).
51. Pace, C. N., Vajdos, F., Fee, L., Grimsley, G. & Gray, T. How to measure and predict the molar absorption coefficient of a protein. Protein Sci. 4, 2411-2423 (1995).
52. Chen, Y. R. & Glabe, C. G. Distinct early folding and aggregation properties of Alzheimer amyloid-beta peptides Abeta40 and Abeta42: stable trimer or tetramer formation by Abeta42. J. Biol. Chem. 281, 24414-24422 (2006).
53. Chen, Y. R. & Clark, A. C. Kinetic traps in the folding/unfolding of procaspase-1 CARD domain. Protein Sci. 13, 2196-2206 (2004).
54. Chen, W. T., Liao, Y. H., Yu, H. M., Cheng, I. H. & Chen, Y. R. Distinct effects of Zn2+, Cu2+, Fe3+, and Al3+ on amyloid-β stability, oligomerization, and aggregation: amyloid-β destabilization promotes annular protofibril formation. J. Biol. Chem. 286, 9646-9656 (2011).
55. Ni, C. L., Shi, H. P., Yu, H. M., Chang, Y. C. & Chen, Y. R. Folding stability of amyloid-{beta} 40 monomer is an important determinant of the nucleation kinetics in fibrillization. FASEB J. 25, 1390-1401 (2011).
56. Bitan, G., Lomakin, A. & Teplow, D. B. Amyloid beta-protein oligomerization: prenucleation interactions revealed by photo-induced cross-linking of unmodified proteins. J. Biol. Chem. 276, 35176-35184 (2001).